Kura Oncology (NASDAQ:KURA) Receives Overweight Rating from Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a report released on Monday,Benzinga reports.

Several other equities research analysts also recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a report on Tuesday, November 19th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, UBS Group began coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Down 2.3 %

Kura Oncology stock opened at $10.29 on Monday. The stock has a 50 day moving average of $15.68 and a two-hundred day moving average of $18.76. Kura Oncology has a twelve month low of $9.68 and a twelve month high of $24.17. The stock has a market capitalization of $800.15 million, a price-to-earnings ratio of -4.36 and a beta of 0.75. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently modified their holdings of KURA. Price T Rowe Associates Inc. MD increased its stake in Kura Oncology by 17.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Aaron Wealth Advisors LLC grew its holdings in Kura Oncology by 2.4% in the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after purchasing an additional 1,673 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Kura Oncology by 4.6% in the second quarter. Bank of New York Mellon Corp now owns 255,897 shares of the company’s stock valued at $5,269,000 after buying an additional 11,212 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Kura Oncology by 34.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock worth $372,000 after buying an additional 4,654 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.